pembrolizumab
MD Anderson Researchers Explore Neoadjuvant Keytruda in MSI-high Solid Tumors
The study presented at the ESMO Congress also suggested that ctDNA testing may predict which patients should have surgery to remove their tumors and those who can do without it.
CHMP Recommends Merck's Keytruda Plus Chemo for PD-L1-Positve TNBC
The committee recommended the combo for PD-L1-positive advanced cancers based on data from the Phase III KEYNOTE-355 trial.
UK's NICE Supports Keytruda With Chemo for PD-L1 Positive Esophageal Cancer Patients
The agency said the life-extending treatment would be cost-effective for NHS to provide as a first-line option for certain esophageal and gastro-esophageal junction cancers.
IO Biotech Studying Cancer Vaccine With Merck's Keytruda in Advanced Melanoma Patients
The company will study the activity of IO102-IO103 with Merck's anti-PD-1 drug in advanced melanoma patients and look for biomarkers of response.
Merck Nets Two Keytruda Approvals in Japan for TNBC, Colon Cancer
Japanese regulators approved pembrolizumab for PD-L1-positive triple-negative breast cancer and microsatellite instability-high colorectal cancer patients.Â